Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | EML4 - ALK |
| Therapy | Alectinib |
| Indication/Tumor Type | papillary renal cell carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| EML4 - ALK | papillary renal cell carcinoma | predicted - sensitive | Alectinib | Case Reports/Case Series | Actionable | In a clinical study, three previously treated patients with metastatic papillary renal cell carcinoma harboring an EML4-ALK fusion were sensitive to treatment with Alecensa (alectinib), demonstrating a clinical and radiographic response in one patient, a radiographic response and ongoing stable disease for 9 months in another patient, and regression of multiple metastatic sites in the third patient (PMID: 29685646). | 29685646 |
| EML4 - ALK | papillary renal cell carcinoma | predicted - sensitive | Alectinib | Case Reports/Case Series | Actionable | In a clinical case study, Alecensa (alectinib) treatment resulted in 2 partial responses with a time to treatment failure of 21.9 months and 24.4 months among 2 patients with papillary renal cell carcinoma harboring EML4-ALK (PMID: 42150148). | 42150148 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (29685646) | Responses to Alectinib in ALK-rearranged Papillary Renal Cell Carcinoma. | Full reference... |
| (42150148) | Use of ALK Inhibitors in Patients With Nonlung Malignancies Bearing ALK Alteration Prolongs Treatment Duration. | Full reference... |